component of oligomeric golgi complex 4
1. Normal Function
The COG4 gene provides instructions for making a protein called component of oligomeric Golgi complex 4 (COG4). As its name suggests, COG4 is one piece of a group of proteins known as the conserved oligomeric Golgi (COG) complex. This complex is important for maintaining normal functions in the Golgi apparatus, which is a cell structure in which newly produced proteins are modified so they can carry out their functions. An example of a protein modification process that occurs in the Golgi apparatus is glycosylation, by which sugar molecules (oligosaccharides) are attached to proteins and fats. Glycosylation modifies proteins so they can perform a wider variety of functions.
The COG complex plays an important role in a process called retrograde transport, through which proteins are moved from the Golgi apparatus to another cellular structure called the endoplasmic reticulum. Among its many functions, the endoplasmic reticulum folds and modifies newly formed proteins so they have the correct 3-dimensional shape. This transport pathway is called retrograde because it is in reverse order of the usual process for newly produced proteins. New proteins undergo initial processing in the endoplasmic reticulum then move to the Golgi apparatus for further modification before being released from the cell (secreted). Retrograde transport is important for sending unneeded proteins to the endoplasmic reticulum to get recycled and for relocating misplaced proteins within the cell.
For retrograde transport, proteins first must be incorporated into sac-like structures called vesicles that get attached to the Golgi apparatus membrane. The COG complex controls the attachment (tethering) of the vesicles to the Golgi membrane in preparation for transport. Once the proteins are incorporated, the vesicles detach and carry the proteins to the endoplasmic reticulum.
2. Health Conditions Related to Genetic Changes
2.1. Saul-Wilson Syndrome
At least two mutations in the COG4 gene have been found to cause Saul-Wilson syndrome, a condition characterized by short stature (dwarfism) and other skeletal abnormalities. The mutations change single DNA building blocks (nucleotides) in the COG4 gene. These two nucleotide changes result in the same alteration in the COG4 protein. The protein building block (amino acid) glycine is switched to the amino acid arginine at position 516 in the protein (written as Gly516Arg or G516R).
The amino acid change in the COG4 protein alters its structure, but the abnormal protein is still able to be a part of the COG complex. When the abnormal COG4 protein is incorporated into the COG complex, retrograde transport of proteins between the Golgi apparatus and the endoplasmic reticulum is increased. Because the COG4 gene mutations enhance the COG complex's function, they are described as "gain-of-function." It is unclear how increased retrograde transport impairs bone growth and leads to the signs and symptoms of Saul-Wilson syndrome.
2.2. Other Disorders
Mutations in the COG4 gene have also been found to cause a condition called COG4-congenital disorder of glycosylation (COG4-CDG). This condition often leads to developmental delay, intellectual disability, seizures, and an unusually small head size (microcephaly). Mutations in the COG4 gene that cause COG4-CDG reduce the amount of COG4 protein or eliminate it completely, which likely impairs COG complex formation and its role in maintaining the normal function of the Golgi apparatus. A dysfunctional Golgi apparatus results in abnormal protein glycosylation, which can affect multiple body systems, leading to the signs and symptoms of COG4-CDG.
3. Other Names for This Gene
- COD1, S. CEREVISIAE, HOMOLOG OF
- COG4 gene
The entry is from https://medlineplus.gov/genetics/gene/cog4
- Blackburn JB, D'Souza Z, Lupashin VV. Maintaining order: COG complex controls Golgi trafficking, processing, and sorting. FEBS Lett. 2019Sep;593(17):2466-2487. doi: 10.1002/1873-3468.13570.
- Ferreira C. Saul-Wilson Syndrome. 2020 Feb 20. In: Adam MP, Ardinger HH, PagonRA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews®[Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Availablefrom http://www.ncbi.nlm.nih.gov/books/NBK554080/
- Ferreira CR, Xia ZJ, Clément A, Parry DA, Davids M, Taylan F, Sharma P,Turgeon CT, Blanco-Sánchez B, Ng BG, Logan CV, Wolfe LA, Solomon BD, Cho MT,Douglas G, Carvalho DR, Bratke H, Haug MG, Phillips JB, Wegner J, Tiemeyer M,Aoki K; Undiagnosed Diseases Network; Scottish Genome Partnership, Nordgren A,Hammarsjö A, Duker AL, Rohena L, Hove HB, Ek J, Adams D, Tifft CJ, Onyekweli T,Weixel T, Macnamara E, Radtke K, Powis Z, Earl D, Gabriel M, Russi AHS, Brick L, Kozenko M, Tham E, Raymond KM, Phillips JA 3rd, Tiller GE, Wilson WG, Hamid R,Malicdan MCV, Nishimura G, Grigelioniene G, Jackson A, Westerfield M, Bober MB,Gahl WA, Freeze HH. A Recurrent De Novo Heterozygous COG4 Substitution Leads toSaul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered ProteoglycanGlycosylation. Am J Hum Genet. 2018 Oct 4;103(4):553-567. doi:10.1016/j.ajhg.2018.09.003.
- Ferreira CR, Zein WM, Huryn LA, Merker A, Berger SI, Wilson WG, Tiller GE,Wolfe LA, Merideth M, Carvalho DR, Duker AL, Bratke H, Haug MG, Rohena L, HoveHB, Xia ZJ, Ng BG, Freeze HH, Gabriel M, Russi AHS, Brick L, Kozenko M, Earl DL, Tham E, Nishimura G, Phillips JA 3rd, Gahl WA, Hamid R, Jackson AP, GrigelionieneG, Bober MB. Defining the clinical phenotype of Saul-Wilson syndrome. Genet Med. 2020 May;22(5):857-866. doi: 10.1038/s41436-019-0737-1.
- Reynders E, Foulquier F, Leão Teles E, Quelhas D, Morelle W, Rabouille C,Annaert W, Matthijs G. Golgi function and dysfunction in the first COG4-deficientCDG type II patient. Hum Mol Genet. 2009 Sep 1;18(17):3244-56. doi:10.1093/hmg/ddp262.
- Richardson BC, Smith RD, Ungar D, Nakamura A, Jeffrey PD, Lupashin VV, HughsonFM. Structural basis for a human glycosylation disorder caused by mutation of theCOG4 gene. Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13329-34. doi:10.1073/pnas.0901966106.